The Safety, Acceptability and Efficacy of Alena

Sponsor
Aya Technologies Limited (Industry)
Overall Status
Completed
CT.gov ID
NCT05858294
Collaborator
(none)
102
1
2
1.6
64.7

Study Details

Study Description

Brief Summary

The present study is a randomised controlled trial that seeks to investigate the safety, acceptability and efficacy and safety of the Alena CBT programme as a treatment for social anxiety disorder.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Behavioral Therapy programme
N/A

Detailed Description

This is a 6-week web-based parallel-group unblinded randomised controlled trial with a 4-week intervention period and a 2-week follow-up post intervention. Participants are randomly allocated to receive access to the Alena CBT programme or to a wait list control group, in a 1:1 ratio. The programme consists of CBT-based therapy for social anxiety based on the Clark and Wells model.

Study Design

Study Type:
Interventional
Actual Enrollment :
102 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Safety, Acceptability and Efficacy of Alena, a Modularized CBT-based Mobile App Intervention for Social Anxiety: a Randomised Controlled Trial
Actual Study Start Date :
Oct 31, 2022
Actual Primary Completion Date :
Dec 4, 2022
Actual Study Completion Date :
Dec 18, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cognitive Behavioral Therapy program

Access to the "Alena" CBT-based therapy programme for 4 weeks. Each of the four therapy modules gradually became available on a weekly basis until all four were available in the final intervention week. Participants were instructed to complete one module per week. Each therapy module consisted of psychoeducational content, guided psychological reflection and perspective-taking exercises, and, where appropriate, skills training exercises such as attention training, public speaking, and exposure experiments to be completed in real life.

Behavioral: Cognitive Behavioral Therapy programme
This mobile application comprised CBT-based therapy for social anxiety based on the Clark and Wells model

No Intervention: Waitlist control

Waitlist control. Participants in this arm were given access to the CBT content at the end of the 4-week trial period.

Outcome Measures

Primary Outcome Measures

  1. Questionnaires assessing negative effects from using the app and adverse health events [Week 4 (primary endpoint)]

    The Intervention group was asked "Have you experienced any negative effects from using the Alena app? This could be a physical or emotional effect that you believe you have experienced as a result of using the app and/or engaging in the app therapy." Both groups were asked: "Have you experienced any new, serious negative health effects in the past week? This includes having to see your GP for a new reason, going to hospital, or being otherwise very unwell in terms of your physical or mental health." If participants responded positively to either question, they were prompted for additional details and to rate the severity of the experience.

  2. Questionnaires assessing negative effects from using the app and adverse health events [Week 6 (2-week follow-up post-intervention)]

    The Intervention group was asked "Have you experienced any negative effects from using the Alena app? This could be a physical or emotional effect that you believe you have experienced as a result of using the app and/or engaging in the app therapy." Both groups were asked: "Have you experienced any new, serious negative health effects in the past week? This includes having to see your GP for a new reason, going to hospital, or being otherwise very unwell in terms of your physical or mental health." If participants responded positively to either question, they were prompted for additional details and to rate the severity of the experience.

  3. Questionnaire assessing satisfaction, helpfulness and ease of use [Week 4 (primary endpoint)]

    Participants were asked how satisfied they were with the app overall (Likert rating scale from very dissatisfied to very satisfied); how helpful they found the app (Likert ratings from very unhelpful to very helpful); how likely they would be to recommend the app (Likert ratings from very unlikely to very likely); how easy they found using the app (Likert ratings from very difficult to very easy); whether they got to the end of the weekly exercise (yes/no), and what got in the way of completing the exercises, with options provided.

  4. Questionnaire assessing satisfaction, helpfulness and ease of use [Week 6 (2-week follow-up post-intervention)]

    Participants were asked how satisfied they were with the app overall (Likert rating scale from very dissatisfied to very satisfied); how helpful they found the app (Likert ratings from very unhelpful to very helpful); how likely they would be to recommend the app (Likert ratings from very unlikely to very likely); how easy they found using the app (Likert ratings from very difficult to very easy); whether they got to the end of the weekly exercise (yes/no), and what got in the way of completing the exercises, with options provided.

Secondary Outcome Measures

  1. Social phobia inventory (SPIN) [Week 4 (primary endpoint)]

    The SPIN was designed to assess the full spectrum of symptoms that characterise social anxiety, including fear, avoidance and physiological components. Total score ranging from 0 to 68, with higher scores indicating a worse outcome.

  2. Social phobia inventory (SPIN) [Week 6 (2-week follow-up post-intervention)]

    The SPIN was designed to assess the full spectrum of symptoms that characterise social anxiety, including fear, avoidance and physiological components. Total score ranging from 0 to 68, with higher scores indicating a worse outcome.

  3. Work and Social Adjustment Scale (WSAS) [Week 4 (primary endpoint)]

    The WSAS measures the extent to which the respondent's problem impairs their ability to carry out day-to-day activities, such as work, home management and social leisure activities. Total score ranging from 0 to 40, with higher scores indicating higher impairment

  4. Work and Social Adjustment Scale (WSAS) [Week 6 (2-week follow-up post-intervention)]

    The WSAS measures the extent to which the respondent's problem impairs their ability to carry out day-to-day activities, such as work, home management and social leisure activities. Total score ranging from 0 to 40, with higher scores indicating higher impairment

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 35 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • female

  • aged between 18 and 35 years old (inclusive)

  • located in the UK

  • fluent in English

  • comfortable taking part in a study that included deception (due to the nature of the cognitive assessments)

  • had an iPhone and daily access to an internet connection

  • scored over 30 on the Social Phobia Inventory (SPIN; indicating at least moderate social anxiety).

Exclusion Criteria:
  • currently undergoing any mental health therapy

  • changed the usual mental health medication or dosage within the past eight weeks

  • scored eight or above on the Alcohol Use Disorders Identification Test for consumption (AUDIT-C; indicating higher risk of alcohol dependence)

  • scored two or above on the adapted drug questions (indicating higher risk of drug dependence)

  • had previously participated in scientific studies or user research undertaken by Alena

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aya Technologies Limited London United Kingdom

Sponsors and Collaborators

  • Aya Technologies Limited

Investigators

  • Principal Investigator: Mandana Ahmadi, PhD, Aya Technologies Limited

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Aya Technologies Limited
ClinicalTrials.gov Identifier:
NCT05858294
Other Study ID Numbers:
  • Alena CBT RCT 2022
First Posted:
May 15, 2023
Last Update Posted:
May 15, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Aya Technologies Limited
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 15, 2023